Results 151 to 160 of about 47,200 (309)

Efficacy and safety of non‐vitamin K antagonist oral anticoagulants versus warfarin in atrial fibrillation and kidney failure under hemodialysis: A meta‐analysis of controlled randomized trials

Journal of Arrhythmia, Volume 41, Issue 3, June 2025.
Rivaroxaban or apixaban is as safe and effective as VKAs in patients with AF and kidney failure with hemodialysis. Even on oral anticoagulants, these patients remain at high risk of cardiovascular events and all‐cause mortality. Integrated care and holistic management are important for this high‐risk population. Abstract Background Atrial fibrillation (
Ting‐Yung Chang, Yi‐Hsin Chan, Tze‐Fan Chao, Chin‐Yu Lin, Yenn‐Jiang Lin, Shih‐Lin Chang, Li‐Wei Lo, Yu‐Feng Hu, Fa‐Po Chung, Shih‐Ann Chen   +9 more
wiley   +1 more source

Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.

New England Journal of Medicine, 2013
BACKGROUND Dabigatran, which is administered in a fixed dose and does not require laboratory monitoring, may be suitable for extended treatment of venous thromboembolism.
S. Schulman, C. Kearon, A. Kakkar, S. Schellong, H. Eriksson, David Baanstra, A. M. Kvamme, J. Friedman, P. Mismetti, S. Goldhaber   +9 more
semanticscholar   +1 more source

Atrial fibrillation patients presenting to an emergency department successfully managed with a next‐day community follow‐up pathway: A before‐and‐after cohort study

Emergency Medicine Australasia, Volume 37, Issue 3, June 2025.
A rate‐and‐wait strategy for managing patients presenting to ED with AF, incorporating rate control and anticoagulation with next‐day community follow‐up has not increased hospital admission, re‐presentation, cardioversion or AE rates, compared to hospital‐based follow‐up.
Finn Brokenshire, John W Pickering, Ibrahim S Al‐Busaidi, Martin Than, Richard Troughton, Kaleb Addy, Laura R Joyce   +6 more
wiley   +1 more source

IMPACT OF ABCB1 AND CES1 GENETIC POLYMORPHISMS ON TROUGH STEADY-STATE DABIGATRAN CONCENTRATIONS IN PATIENTS AFTER ENDOPROSTHESIS OF KNIFE JOIN

Атеротромбоз, 2018
Oral anticoagulants are widely used to prevent thromboembolic events in patients following total knee arthroplasty [1]. The genetic characteristics of patients affect the efficacy and safety of anticoagulants [2].
D. A. Sychev, A. N. Levanov, T. V. Shelekhova, P. O. Bochkov, N. Р. Denisenko, K. A. Ryzhikova, K. В. Mirzaev, E. A. Grishina, M. A. Gavrilov   +8 more
doaj   +1 more source

Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study

British medical journal, 2015
Objective To determine the real world risk of gastrointestinal bleeding associated with the use of the novel oral anticoagulants dabigatran and rivaroxaban compared with warfarin. Design Retrospective, propensity matched cohort study. Setting: Optum Labs
N. Abraham, Sonal Singh, G. Alexander, H. Heien, L. Haas, W. Crown, N. Shah   +6 more
semanticscholar   +1 more source

Medication Utilization Evaluation of Dabigatran and Rivaroxaban within a Large, Multicenter Health System. [PDF]

, 2013
Objective. The objective of this medication utilization evaluation (MUE) was to determine the appropriateness of dabigatran and rivaroxaban while also reviewing outcomes for safety and effectiveness within a large, multi-center health system. Methods.
Doolin, Meagan, Issacs, Alex N., Morse, Courtney, Nisly, Sarah A., Shiltz, Erin   +4 more
core   +1 more source

Evaluation of the DOAC-Stop Procedure by LC-MS/MS Assays for Determining the Residual Activity of Dabigatran, Rivaroxaban, and Apixaban

Clinical and applied thrombosis/hemostasis, 2019
The effect of direct oral anticoagulants (DOACs) on laboratory tests dependent on the production of their targets, factor IIa and factor Xa (FXa), is a well-known problem and can cause both false positive and negative results.
L. Slavík, J. Jáčová, D. Friedecký, J. Úlehlová, Z. Tauber, J. Procházková, A. Hluší, M. Palová   +7 more
semanticscholar   +1 more source

Oral Antithrombotic Inhibitors: Dabigatran Etexilate, Meeting an Unmet Need? [PDF]

, 2009
Russell D. Hull
openalex   +1 more source

Dabigatran Challenges Warfarin’s Superiority for Stroke Prevention in Atrial Fibrillation [PDF]

, 2010
Neil Schwartz, Gregory W. Albers
openalex   +1 more source

Dabigatran etexilate [PDF]

British Journal of Clinical Pharmacology, 2010
Eline A. Dubois, Adam F. Cohen
openaire   +3 more sources